Evaluation of laboratory disturbance risk when adding low-dose cotrimoxazole for PJP prophylaxis to regimens of high-grade glioma patients taking RAAS inhibitors

Abstract

Background

Cotrimoxazole is associated with the development of hyponatremia, hyperkalemia and elevated serum creatinine, especially when combined with inhibitors of the renin–angiotensin–aldosterone system (RAAS). Pneumocystis jirovecii pneumonia (PJP) prophylaxis is the standard of care for high-grade glioma (HGG) patients receiving temozolomide concurrently with radiotherapy, low-dose cotrimoxazole being the preferred agent. Many of these patients are also taking renin–angiotensin–aldosterone system inhibitors, however the risk of significant laboratory disturbance in these patients remains undescribed.

Objective

We evaluated whether high-grade glioma patients taking renin–angiotensin–aldosterone system inhibitors receiving low-dose cotrimoxazole for Pneumocystis jirovecii pneumonia prophylaxis are at additional risk of laboratory disturbances in comparison with their non-renin–angiotensin–aldosterone system counterparts.

Methods

We conducted a retrospective chart review of adult neuro-oncology patients treated for WHO Grade III or IV glioma between 2013 and 2016. Patient serum Na, K, creatinine, and eGFR were compared (renin–angiotensin–aldosterone system vs. non-renin–angiotensin–aldosterone system) using the chi-square test. Binary logistic regression analysis was then performed to account for differences between cohorts.

Results

Of 63 patients (35 non-renin–angiotensin–aldosterone system, 28 renin–angiotensin–aldosterone system), patients in the renin–angiotensin–aldosterone system cohort were more likely to experience a laboratory disturbance (odds ratio=3.17, p = 0.03). Overall, these disturbances were moderate, but were slightly more common and slightly more severe in the renin–angiotensin–aldosterone system cohort.

Conclusion

Adding low-dose cotrimoxazole for Pneumocystis jirovecii pneumonia prophylaxis to the regimens of patients with high-grade glioma taking renin–angiotensin–aldosterone system inhibitors increases the risk of laboratory disturbances. While these are generally moderate, some patients are at risk of significant electrolyte abnormalities requiring intervention.

Keywords

Cotrimoxazole Pneumocystis PJP prophylaxis RAAS renin-angiotensin-aldosterone system inhibitor glioma hyperkalemia hyponatremia acute renal injury

Get full access to this article

View all access options for this article.

References

Lawson

Jick

. Adverse reactions to co-trimoxazole in hospitalized medical patients. Am J Med Sci 1978; 275: 53–57.

Jick

. Adverse reactions to trimethoprim-sulfamethoxazole in hospitalized patients. Rev Infect Dis 1982; 4: 426–428.

Torre-Cisneros

De la Mata

Pozo

et al.

Randomized trial of weekly sulfadoxine/pyrimethamine vs. daily low-dose trimethoprim-sulfamethoxazole for the prophylaxis of Pneumocystis carinii pneumonia after liver transplantation. Clin Infect Dis 1999; 29: 771–774.

Stern A, Green H, Paul M, et al. Prophylaxis for pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients. Cochrane Database Syst Rev, https://onlinelibrary-wiley-com.web.bisu.edu.cn/doi/10.1002/14651858.CD005590.pub3/epdf (2014, accessed 16 December 2016).

Brogden

Carmine

Heel

et al.

Trimethoprim: a review of its antibacterial activity, pharmacokinetics and therapeutic use in urinary tract infections. Drugs 1982; 23: 405–430.

Eiam-Ong

Kurtzman

Sabatini

. Studies on the mechanism of trimethoprim-induced hyperkalemia. Kidney Int 1996; 49: 1372–1378.

Velázquez

Perazella

Wright

et al.

Renal mechanism of trimethoprim-induced hyperkalemia. Ann Intern Med 1993; 119: 296–301.

Weir

Juurlink

Gomes

et al.

Beta-blockers, trimethoprim-sulfamethoxazole, and the risk of hyperkalemia requiring hospitalization in the elderly: a nested case–control study. Clin J Am Soc Nephrol 2010; 5: 1544–1551.

Gentry

Nguyen

. An evaluation of hyperkalemia and serum creatinine elevation associated with different dosage levels of outpatient trimethoprim-sulfamethoxazole with and without concomitant medications. Ann Pharmacother 2013; 47: 1618–1626.

10.

Mori

Kuroda

Imamura

et al.

Hyponatremia and/or hyperkalemia in patients treated with the standard dose of trimethoprim-sulfamethoxazole. Intern Med 2003; 42: 665–669.

11.

Perazella

Mahnensmith

. Trimethoprim-sulfamethoxazole: hyperkalemia is an important complication regardless of dose. Clin Nephrol 1996; 46: 187–92.

12.

Agodoa

. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA 2001; 285: 2719–2719.

13.

The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting–enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145–153.

14.

The ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008; 358: 1547–1559.

15.

Rocha

Williams

. Rationale for the use of aldosterone antagonists in congestive heart failure. Drugs 2002; 62: 723–731.

16.

Schrier

Masoumi

Elhassan

. Aldosterone: role in edematous disorders, hypertension, chronic renal failure, and metabolic syndrome. Clin J Am Soc Nephrol 2010; 5: 1132–1140.

17.

Reardon

Macpherson

. Hyperkalemia in outpatients using angiotensin-converting enzyme inhibitors. How much should we worry? Arch Intern Med 1998; 158: 26–32.

18.

Sadjadi

McMillan

Jaipaul

et al.

A comparative study of the prevalence of hyperkalemia with the use of angiotensinconverting enzyme inhibitors versus angiotensin receptor blockers. Ther Clin Risk Manag 2009; 5: 547–552.

19.

Wrenger

Müller

Moesenthin

et al.

Interaction of spironolactone with ACE inhibitors or angiotensin receptor blockers: analysis of 44 cases. BMJ 2003; 327: 147–149.

20.

Antoniou

Gomes

Juurlink

et al.

Trimethoprim-sulfamethoxazole-induced hyperkalemia in patients receiving inhibitors of the renin-angiotensin system: a population-based study. Arch Intern Med 2010; 170: 1045–1049.

21.

Antoniou

Gomes

Mamdani

et al.

Trimethoprim-sulfamethoxazole induced hyperkalaemia in elderly patients receiving spironolactone: nested case-control study. BMJ 2011; 343: d5228–d5228.

22.

Nguyen

Gentry

Furrh

. A comparison of adverse drug reactions between high- and standard-dose trimethoprim-sulfamethoxazole in the ambulatory setting. Curr Drug Saf 2013; 8: 114–119.

23.

Ingelfinger

. A new era for the treatment of hyperkalemia? N Engl J Med 2015; 372: 2015–2017.

24.

Louis

Ohgaki

Wiestler

et al.

The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007; 114: 97–109.

25.

Stupp

Mason

van den Bent

et al.

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987–996.

26.

Stupp

Hegi

Mason

et al.

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009; 10: 459–466.

27.

Roa

Brasher

Bauman

et al.

Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. J Clin Oncol 2004; 22: 1583–1588.

28.

Wen

Schiff

Kesari

et al.

Medical management of patients with brain tumors. J Neurooncol 2006; 80: 313–332.

29.

National Comprehensive Cancer Network. Prevention and treatment of cancer-related infections (version 2), www.nccn.org/professionals/physician_gls/pdf/infections.pdf (2017, accessed 11 October 2017).

30.

National Comprehensive Cancer Network. Central Nervous System Cancers (version 1), www.nccn.org/professionals/physician_gls/pdf/cns.pdf (2017, accessed 11 October 2017).

31.

Population estimates on July 1st, by age and sex, Table: 17-10-0005-01. Statistics Canada, www.statcan.gc.ca/tables-tableaux/sum-som/l01/cst01/demo02a-eng.htm (accessed 17 December 2017).

32.

Vassar

Holzmann

. The retrospective chart review: important methodological considerations. J Educ Eval Health Prof 2013; 10: 12–12.

33.

Higashioka

Niiro

Yoshida

et al.

Renal insufficiency in concert with renin-angiotensin-aldosterone inhibition is a major risk factor for hyperkalemia associated with low-dose trimethoprim-sulfamethoxazole in adults. Intern Med 2016; 55: 467–471.

34.

Fraser

Avellaneda

Graviss

et al.

Acute kidney injury associated with trimethoprim/sulfamethoxazole. J Antimicrob Chemother 2012; 67: 1271–1277.

35.

Marinella

. Hyperkalemia in elderly patients associated with trimethoprim-sulfamethoxazole. J Geriatr Drug Ther 1996; 11: 93–97.

36.

Hess

Broglio

Bondy

. Adult glioma incidence trends in the United States, 1977–2000. Cancer 2004; 101: 2293–2299.

37.

National Kidney Foundation . K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, clasification and stratification. Am J Kidney Dis 2002; 39: 1–266.

38.

National Cancer Institute Division of Cancer Treatment and Diagnosis. Common Terminology Criteria for Adverse Events (CTCAE) v4.0, https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf (accessed 18 December 2016).

39.

Alberta Health Services. Laboratory services chemistry reference intervals, www.albertahealthservices.ca/assets/wf/lab/wf-lab-chemistry-reference-intervals.pdf (accessed 17 December 2016).